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To date, 146 different mutations in superoxide dismutase 1 (SOD1) have been identiﬁed in patients with famil-
ial amyotrophic lateral sclerosis (ALS). The mean age of disease onset in patients inheriting mutations in
SOD1 is 45–47 years of age. However, although the length of disease duration is highly variable, there are
examples of consistent disease durations associated with speciﬁc mutations (e. g. A4V, less than 2 years).
In the present study, we have used a large set of data from SOD1-associated ALS pedigrees to identify cor-
relations between disease features and biochemical/biophysical properties of more than 30 different variants
of mutant SOD1. Using a reliable cell culture assay, we show that all ALS-associated mutations in SOD1
increase the inherent aggregation propensity of the protein. However, the relative propensity to do so
varied considerably among mutants. We were not able to explain the variation in aggregation rates by differ-
ences in known protein properties such as enzyme activity, protein thermostability, mutation position or
degree of change in protein charge. Similarly, we were not able to explain variability in the duration of disease
in SOD1-associated ALS pedigrees by these properties. However, we ﬁnd that the majority of pedigrees in
which patients exhibit reproducibly short disease durations are associated with mutations that show a
high inherent propensity to induce aggregation of SOD1.
INTRODUCTION
Familial amyotrophic lateral sclerosis (ALS) is an invariably
fatal neurodegenerative disease that principally affects upper
and lower motor neurons. A subset of familial ALS cases
(12–20%) are caused by mutations in superoxide dismutase
1 (SOD1), with 146 different mutations described in families
or more rarely in an individual apparently sporadic case
(www.alsod.org). Eleven different mutations have been
expressed in transgenic mice and rat models (1–15), which
develop ALS-like phenotypes that include hindlimb weak-
ness, progressive generalized paralysis and muscle atrophy.
Recently, recessive inheritance of a SOD1 mutation has
been described in dogs that develop ALS-like disease (16).
In all these models, there is evidence that the levels of
expression are critical to induce disease. For example,
there are mice that express the G37R or D90A SOD1 that
do not develop disease unless bred to homozygosity (8,12).
Similarly, disease is absent in mice expressing low levels
of A4V SOD1 but evident when the levels of total SOD1
are raised by co-expression with wild-type (WT) SOD1
(1). Additionally, very aggressive phenotypes are found in
the rare consanguineous human cases (G27DGP, L84F,
N86S, L126S) (17–19). Thus, the levels of expression of
SOD1 mutant proteins seem to play an important role in
disease.
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is accompanied by the accumulation of detergent-insoluble
aggregated forms of mutant SOD1 (1,12,13,15,20–22). In
human SOD1-associated ALS, there is similar evidence that
mutant SOD1 aggregation is a pathological feature (20).
Thus, there seems to be a clear correlation between the pres-
ence of detergent-insoluble aggregated forms of mutant
SOD1 in spinal cords and disease (23). Importantly, aggre-
gated forms of mutant SOD1 that display similar properties
of detergent insolubility can be produced in cultured cells
(22–25), representing an efﬁcient system to screen and
study aggregation of ALS mutants. SOD1-associated ALS
mutations are spread throughout the 153 amino acid protein
sequence with the vast majority of point mutations occurring
at highly conserved amino acids (24). Eighty codons in
SOD1 are known to be targets of mutation that give rise to
the ALS phenotype; in some cases, multiple amino acid sub-
stitutions occur at one site (up to six for G93). It is well estab-
lished that speciﬁc mutations are associated with disease of
short- or long-clinical course (26). Examples of short disease
course include the A4V mutation (less than 2 years) (27),
whereas mutations such as H46R are associated with a long-
disease course (more than 10 years) (28). A recent study
used a variety of biophysical data to calculate aggregation
rates for different ALS mutants, suggesting that aggregation
of mutant protein could be a key factor in disease progression
(29). Here, we have used our cell culture model to analyze a
total of 33 SOD1-associated ALS mutations in regards to
their ability to form detergent-insoluble aggregates, including
different mutation substitutions at the same codon. By this
approach, we assess how measured aggregation potentials
relate to known biophysical/biochemical characteristics and
examine whether aggregation propensities correlate to
disease features in human ALS patients.
RESULTS
Large variability in aggregation among SOD1-associated
ALS mutants
Our ﬁrst analysis of 21 mutant SOD1 proteins demonstrated
that all are capable of forming detergent-insoluble SOD1
aggregates in cells within 24 h (Fig. 1A). Quantiﬁcation of
the aggregation propensity, which is calculated from the
ratio of insoluble to soluble forms of mutant SOD1 in cell
lysates, of different mutations showed signiﬁcant differences
from WT SOD1 (Fig. 1B). To normalize data from different
experiments, we chose to use the aggregation propensity of
A4V SOD1 as the reference mutant [assigning one to the
mean aggregation propensity of A4V, as previously described
(22,23)]. Most mutations analyzed in Fig. 1A are of similar, or
higher, aggregation propensity to A4V. Several mutants pos-
sessed aggregation propensities lower than that of A4V
(G93D, E21G, E21K and G41D). In the cases in which
more than one mutation occurred at a particular codon, we
often observed signiﬁcantly different levels of aggregated
protein for each individual mutation at one position
(Fig. 1B); examples include A4V versus T (P ¼ 0.0168);
G93A versus D (P ¼ 0.0078), R (P ¼ 0.0056) or S (P ¼
0.0222); G41D versus S (P ¼ 0.0128) and E100G versus K
(P ¼ 0.0160). We also observed examples in which different
amino acid changes at the same position did not differentially
Figure 1. Large variability in aggregation among SOD1-associated ALS mutants. (A and C) Immunoblots of detergent insoluble (P2) and soluble fractions (S1)
of HEK293FT cells transfected with WT or mutant SOD1 for 24 h. UT: untransfected cells. (B and D) Quantiﬁcation of the relative aggregation propensity of the
WT and mutant SOD1 as described in Materials and Methods. Bars represent mean+SEM of three or more independent transfection experiments.  P , 0.05,
#P , 0.001.
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0.4934), V (P ¼ 0.111); V14G versus M (P ¼ 0.8766) and
E21G versus K (P ¼ 0.6213). Further studies on additional
SOD1 mutants involving different amino acid substitutions
at the same site demonstrated very high variability in aggrega-
tion propensities. Mutation of D101 or V148 to G induced the
formation of very high levels of detergent-insoluble proteins in
24 h (Fig. 1C). D101G together with E100K SOD1 represent
the most aggregation prone proteins analyzed so far.
However, D101N and V148I showed dramatically lower
aggregation levels at 24 h, not different from that of WT
SOD1 (Fig. 1D).
In addition to the slow aggregating D101N and V148I
mutants, we found other mutations in which aggregation
levels resemble those of WT SOD1 protein at 24 h
(Fig. 2A). When compared with G37R, which to date had
been representative of mutants with low potentials to aggre-
gate (23), the H80R, D101N, D125H, E133DE, S134 N and
V148I SOD1 mutants showed even lower potentials to aggre-
gate (Fig. 2A, upper panels). In all cases, high levels of soluble
SOD1 protein were detected for each of the mutants indicating
robust protein expression (Fig. 2A, lower panels). Quantiﬁ-
cation and statistical analysis indicated that the aggregation
propensity of these mutants in 24 h was not different from
WT SOD1 (Fig. 2B). Thus, we identiﬁed, for the ﬁrst time,
SOD1 mutants that do not readily form detergent-insoluble
aggregates in 24 h, showing a similar behavior to WT
SOD1. These ﬁndings were initially viewed as an indication
that aggregation, a priori, may not be necessarily linked to
disease development. In order to more rigorously determine
whether these mutants remain completely soluble, we
extended the interval between transfection and harvest of the
cells from 24 to 48 h. With longer incubation times all
mutants formed detectable levels of detergent-insoluble
protein, whereas WT SOD1 still remained completely
soluble (Fig. 2C). At 48 h, the aggregation propensities of
these mutants were signiﬁcantly different from WT SOD1
(Fig. 2D).
Do speciﬁc biophysical or biochemical properties of SOD1
predict aggregation propensity?
It has been suggested that mutations in SOD1 that decrease the
net negative charge of the protein (eliminating negatively
charged or introducing positively charged amino acids)
causes misfolding and aggregation of mutant SOD1 (30,31).
Many of the ALS-associated point mutations in SOD1
reduce the net negative charge of SOD1; however, three
ALS mutants would be expected to possess a protein charge
more negative than WT SOD1 (Fig. 3, Table 1). Thus, we
asked whether differences in protein charge among the ALS
mutants may explain the variability in the relative rates of
mutant SOD1 aggregation. Some of these changes in protein
charge can be observed in mutations occurring at amino acid
G93. Although some mutations in G93 do not alter the
overall protein charge (Table 1), there is a reduction in the
negative charge of SOD1 when mutating G93 to R, increasing
the aggregation propensity signiﬁcantly compared with those
mutants that do not produce a change in protein charge
(G93R versus A, P ¼ 0.0056; G93R versus C, P ¼ 0.0262;
G93R versus S, P ¼ 0.0012; G93R versus V, P ¼ 0.0325).
Additionally, when G93 is mutated to D, which increases
the negative charge of SOD1, then the levels of aggregated
protein are signiﬁcantly reduced compared with neutral
Figure 2. Some SOD1-associated ALS mutant proteins aggregate slowly. (A and C) Immunoblots of detergent insoluble (P2) and soluble fractions (S1) of
HEK293FT cells transfected with WT or mutant SOD1 for 24 h (A) or 48 h (C). UT: untransfected cells. (B and D) Quantiﬁcation of the relative aggregation
propensity of SOD1 proteins at 24 h (B) and 48 h (D). Bars represent mean+SEM of three or more independent transfection experiments.  P , 0.05,
#P ,
0.001. Note that D101N and V148I SOD1 mutants have been included in this ﬁgure for comparison.
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example of similar ﬁndings is that of mutations at G41,
where G41S presented an aggregation propensity higher than
that of the more negatively charged G41D (P ¼ 0.0128).
Additionally, when mutations occur in E100 (E100G,
E100K), the resulting mutant proteins present less negative
charge than WT SOD1; the E100K mutant shows a more sub-
stantial decrease in negative charge and signiﬁcantly higher
aggregation potential when compared with E100G (P ¼
0.016). Overall, these ﬁndings support the hypothesis that
changes in negative charge may play an important role in
modulating aggregation of SOD1. However, this apparent cor-
relation does not apply to all mutants that alter the negative
charge of SOD1. A good example is the case of mutations
in E21, which can be mutated to either G or K, similar to
mutations in E100. Although E21K SOD1 has a higher
decrease in negative charge, the aggregation propensity
levels of E21G and E21K are not statistically different from
each other (P ¼ 0.6213), with both being very low (Fig. 1).
Another example is that of changes in D101. Decreasing the
negative charge of SOD1 by substituting amino acid D101
by either G or N produces mutant proteins in which aggrega-
tion levels are either very high (D101G) or very low (D101N).
In this case, the same magnitude of decrease in negative
charge produces a very large variability in aggregation rates
(D101G versus D101N, P ¼ 0.0296). Additional examples,
in which a reduction in the negative charge of SOD1 does
not produce dramatic increases in aggregation, are the cases
of H80R, D125H and E133DE (Table 1). To further probe
as to whether the location of the mutation within the protein
may interact with the change in net charge, we graphed
measured aggregation propensity as a function of mutation
charge (Fig. 3) and location (Supplementary Material,
Fig. S1). No obvious pattern emerges to link change in net
charge to inherent aggregation propensities. Further, there
were no obvious correlations between changes in net charge
and disease onset or duration (Supplementary Material,
Fig. S2). Thus, our data suggest that the relative aggregation
propensity of mutant SOD1 is not inextricably linked to
changes in net protein charge. However, we do not discard
the possibility that changes in protein charge, along with
other protein characteristics, could explain the different aggre-
gation propensities of ALS mutants.
Aggregation versus disease
A recent study, using mathematical models, suggested that the
predicted aggregation propensity of SOD1 mutants correlates
with disease duration in humans (29). Here we used data
from our cell culture model to analyze whether our measured
aggregation propensity correlates with patient data on disease
onset and/or duration. We imposed a ﬁlter on the patient data,
focusing on cases in which the number of affected individuals
with a particular mutation met or exceeded ﬁve individuals.
We chose ﬁve individuals as the lower limit, because it
emerged as a natural breakpoint in our data and because this
number of patients allows for a more rigorous estimation of
reproducibility of observed phenotypes. After ﬁltering our
patient data set, we were able to identify 21 different
mutations for which we possessed data on an adequate
number of patients. The data on aggregation propensities of
the different mutants were stratiﬁed into four categories as
explained in Figure 4. For the 21 mutations in the patient
data sets we analyzed, two mutations were categorized as
exhibiting extreme aggregation propensity, 12 of the
mutations ﬁt criteria for high-aggregation propensity, six ﬁt
criteria as moderate and one ﬁts criteria for low aggregation
propensity (see Supplementary Material, Table S1). No
obvious correlation between aggregation propensity and age
of onset was noted (Fig. 4). This outcome was expected
because the mean age of onset is 45–47 years of age for all
SOD1 mutants (Supplementary Material, Table S1). When
we stratiﬁed the mutants by the four criteria described above
and graphed these groups as a function of disease duration,
we noted that mutants exhibiting aggregation propensities
equivalent to or greater than the A4V mutation largely pre-
dicted shorter disease duration in patients (Fig. 5A). Statistical
analysis demonstrated signiﬁcant differences between the
groups of high and moderate aggregation propensities
(unpaired t-test, P ¼ 0.0008). However, inverse correlations
do not exist between aggregation propensity and disease dur-
ation (P ¼ 0.1440, Fig. 5B), possibly because disease duration
in patients with mutations of moderate or low-aggregation pro-
pensity is less predictable. Still, when we focus on the mutants
that show high-aggregation propensities, we ﬁnd that the
majority of patients with these mutations exhibit a rapid
disease course.
DISCUSSION
Studies to date, which have examined a relatively small per-
centage of all ALS mutants, have demonstrated that ALS
mutations in SOD1 increase the propensity of the protein to
Figure 3. Changes in the net negative charge of SOD1 do not predict aggrega-
tion propensity. Mutations in SOD1 that reduce, increase or do not modify the
negative charge of SOD1 present aggregation propensity values that range
from very low to very high; with no particular group representing mutants
of high or low aggregation propensities. Unpaired Student t-tests: no change
in charge mutants versus mutants with reduced charge (P ¼ 0.8711), no
change in charge mutants versus mutants with increased charge (P ¼
0.2556), mutants with reduced charge versus mutants with increased protein
charge (P ¼ 0.5213).
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study raises the total number of SOD1-associated mutants
for which we have measured aggregation propensities to
30% of all known mutants, providing deﬁnitive evidence
that increased aggregation propensity is highly likely to be a
universal feature of mutant SOD1. However, the inherent pro-
pensity of different mutants to produce aggregated protein
varies, even in cases in which multiple mutations target a
single amino acid position. We could not identify a speciﬁc
biochemical or biophysical property of the SOD1-associated
ALS mutants that adequately explains the variability in the
propensity of these mutant proteins to aggregate. Although
causality for variability is unknown, we ﬁnd that the inherent
aggregation propensity of ALS mutants is related to the dur-
ation of disease in ALS patients such that mutants that show
high-aggregation propensities are associated with a greater
risk for short disease duration.
One aspect of our study sought to determine whether varia-
bility in mutant SOD1 aggregation propensity could be
explained by the nature of the amino acid mutation. Mutations
in SOD1 that bring the protein charge to neutrality, or decrease
the negative charge, have been suggested to make it more
prone to aggregate (32,33). More than half of the SOD1 pro-
teins studied here represent mutations affecting a charged
residue or introduce a charged amino acid in place of a non-
charged (Fig. 3). Within this group of mutations that modify
Table 1. Changes in protein charge do not explain aggregation propensity
Aggregation propensity at 24 h No change in net negative charge Reduce net negative charge Increase net negative charge
Low S134N, V148I H80R, D101N, D125H, E133DE
Moderate I113T, L144F, L144S, C111Y E21G, E21K, G37R G41D, G93D, N139K
High C6G, G93C, V14G, C6F, V14M, A4V, G93A,
L84V, G93V, G41S, V148G, G93S
H43R, G85R, D90A, E100G, D124V
Extreme A4T G93R, E100K, D101G
Figure 4. Disease onset is not driven by changes in aggregation propensity. SOD1 mutations with a signiﬁcant number of patients (more than ﬁve) (A), or all
available compiled data (B) grouped in terms of aggregation propensity: Extreme (produces a level of insoluble mutant protein in 24 h that is equal to or greater
than twice that of A4V SOD1—always set at 1), high (aggregate load is similar to A4V in 24 h; aggregation propensities range between 0.7 and 1.7), moderate
(aggregate load is detectable but less than 0.5 in 24 h), slow (no aggregates detected in 24 h—only visible at 48 h). No correlation was found between aggregation
and age of onset (P . 0.05). Note that the mean onset for ALS patients with a SOD1 mutation occurs between 45–47 years of age.
Figure 5. Mutants possessing a higher aggregation propensity correlate with shorter disease duration. (A) Mutations with a signiﬁcant number of patients (more
than ﬁve) grouped in terms or aggregation propensity categories, as explained in Figure 4. Mutations associated with shorter disease durations belong to a group
that present high or extreme aggregation propensities. (B) Non-linear regression of aggregation propensity and disease duration. A statistically signiﬁcant cor-
relation between aggregation and disease duration was not found (P . 0.05).
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all deﬁned levels of aggregation propensity (low, moderate,
high or extreme), not following a clear correlation between a
decrease or increase in protein charge and aggregation rates.
For example, eliminating aspartate in amino acid 101 produces
a low (D101N) or very high (D101G) aggregating protein,
with both proteins producing a decrease in negative charge.
However, when mutations occur at E100, the mutant with a
larger increase in net negative charge has the highest aggrega-
tion propensity (E100K versus G). The E100 and D101 amino
acids are in such close proximity that it seems unlikely that the
different changes in charged amino acids at these two residues
could have very different structural effects on the protein.
Additionally, we have found no obvious correlation between
aggregation propensity and change in charge in amino acids
that concentrate to a particular structure (beta strand versus
non-beta strand regions, surface versus interior; see Sup-
plementary Material, Fig. S1). Finally, we found no obvious
correlation between the magnitude of change in charge by
mutation and disease onset or duration (see Supplementary
Material, Fig. S2). Collectively, these data indicate that
changes in protein charge cannot be the only determining
factor that drives aggregation of mutant SOD1 and that there
is no obvious correlation between charge changes and a
disease feature.
Thermostability is viewed as a measure of the inherent stab-
ility of protein conformation. The mutants we identify here as
slow to aggregate (H80R, D101N, D125H, E133DE, S134N
and V148I) exhibit some of the characteristics of WT SOD1
(see Supplementary Material, Fig. S3). Biophysically, these
mutants show similar H/D exchange kinetics (which assesses
the exposure of residues in the folded protein to solvent) to
WT SOD1 as apo-proteins (34), as well as high levels of
activity (only when metallated) and high thermostability (in
both fully metallated or demetallated states) (34) (see Sup-
plementary Material, Table S2). In contrast, the mutants that
show higher aggregation propensities generally show
reduced thermostability (see Supplementary Material,
Table S2). However, in our tabulation of data on aggregation
levels at 24 h in comparison to thermostability, we noted no
obvious association between low thermostability of the apo-
protein (lacking Cu) and aggregation propensity (see Sup-
plementary Material, Table S2).
Sorting out the role of metal binding in aggregation propen-
sity is somewhat complicated in that different approaches of
assessing metal binding have yielded different outcomes
depending upon whether the protein was produced and iso-
lated from yeast or Sf21 insect cell expression systems.
From the available data, we ﬁnd little evidence to relate
poor metal-binding capacity to the formation of
detergent-insoluble SOD1 aggregates. Three of the low aggre-
gating SOD1 mutants identiﬁed here appear to bind metals
weakly (see Supplementary Material, Table S2). Moreover,
experimental SOD1 mutants in which copper binding ligands
have been abolished do not present a higher propensity to
form detergent-insoluble aggregates than other
SOD1-associated ALS mutations (23). Thus, it does not
appear that low metal-binding capacity correlates to high-
aggregation propensity.
To date, the speciﬁc role or impact that aggregates of
mutant SOD1 have on disease pathogenesis remains unclear.
In some settings, aggregation of mutant protein has been
suggested to reduce toxicity by concentrating an otherwise
toxic protein to a speciﬁc subcellular compartment (35,36);
however, evidence linking aggregates to toxicity is still
largely correlative. All of the SOD1 ALS murine models
that have been analyzed accumulate signiﬁcant amounts of
detergent-insoluble aggregates in tissues most affected by
the disease process (12,15,23,24,37–40). In certain cases, in
which the expression of mutant protein was low, disease
development and/or aggregation was not observed (1,12).
The two interpretations of these ﬁndings are that: (i) aggrega-
tion of mutant SOD1 is critical to the development of disease
or (ii) some other process initiates disease onset and that cells
damaged by the disease process are prone to aggregate mutant
SOD1. Our cell model, however, suggests that a high propen-
sity to aggregate is an inherent characteristic of ALS mutant
SOD1. Our studies have shown that SOD1-associated ALS
mutants display a wide variety of aggregation propensities
that are dependent upon the type and location of the mutation.
Thus, if aggregates have an important role in disease patho-
genesis, then some characteristic of human disease should cor-
relate to the aggregation propensity of the individual mutant.
As noted in Results, the mean age of disease onset in
SOD1-associated ALS is between 45–47 years of age, and
we ﬁnd no obvious correlation between aggregation propen-
sity and age of onset (Fig. 4). However, in our analysis of
clinical data regarding mutations with reliable patient infor-
mation (see Supplementary Material, Table S1), we have
observed that in general there is an inverse relationship
between high-aggregation propensity and disease duration
(Fig. 5). Mutants with higher aggregation propensities
compose a group of mutations in which the clinical data avail-
able is more abundant. In this set of mutants, survival intervals
tend to be shorter; all exhibit a survival of less than 12 years,
although most of them are characterized by survival times of 4
years or less. In contrast, SOD1 mutants with moderate aggre-
gation propensities present survival times ranging 10–18
years. However, these relationships were not absolute as we
found examples of mutants with moderate aggregation propen-
sity in which disease duration is shorter than 10 years: I113T
and L144F SOD1 (see Supplementary Material, Table S1,
Fig. 5). The mutant I113T is known to have incomplete pene-
trance, thus it might be possible that additional factors regulate
disease appearance in certain generations, which would be
responsible for the large variability in disease duration
among patients. Patients harboring the L144F mutation
present complete penetrance, but exhibit a wide range of sur-
vival times (see Supplementary Material, Table S1). It is poss-
ible that as more data becomes available, the number of
exceptions (low aggregation potential linked to rapid pro-
gression) may rise. However, when we include in our analysis
of patient data, all available data including cases with only one
or two patients (see Supplementary Material, Fig. S4), we con-
tinue to observe that high-aggregation propensity shows a
strong association with disease of short duration (less than 5
years). Mutants that show low or moderate aggregation poten-
tials are essentially unpredictable. Overall, we regard the high
3222 Human Molecular Genetics, 2009, Vol. 18, No. 17propensity of a particular mutant to aggregate as a risk factor
for a more rapidly progressing disease.
All of our data in the present study, as well as data derived
from prior studies (23,25) have used the HEK293FT cell as the
model system. We note that we were able to ﬁnd one report in
the literature in which inducible vectors were used in mouse
NSC-34 cells to express a limited number of human mutant
proteins (including A4V, C6F, H46R, G93A, C146R) (41).
These investigators used a very similar approach of determin-
ing the levels of mutant SOD1 in detergent soluble and inso-
luble fractions. After 48 h of induced expression, they
reported that A4V and G93A mutants showed ratios of
insoluble to soluble SOD1 that were similar to what we
report in our current study. We have previously examined
the aggregation of the C6F and C146R mutants in
HEK293FT cells and found high inherent rates of aggregation
(25). Cozzolino reported a similar high rate of aggregation of
these mutants in mouse NSC-34 cells. In contrast, the H46R
mutant showed much lower levels of aggregated mutant
SOD1 in NSC-34 cells; which again is similar to what we
have previously reported for this mutant in our HEK293FT
cell system (23). We also examined aggregation propensities
of human SOD1 by transient transfection of mouse neuroblas-
toma N2a cells (Supplementary Material, Fig. S5). One of the
more interesting pairs of mutants, D101G and D101N, showed
similar aggregation propensities in the N2a cells as was
observed in the HEK293FT cells. Thus, we think that our ﬁnd-
ings in HEK293FT cells reﬂect inherent aggregation propensi-
ties of these mutants that are manifest in other cell types. It is
possible that there are factors unique to motor neurons that
modulate aggregation and that such factors could signiﬁcantly
impact mutant SOD1 folding when present at physiological
levels. However, we argue that the HEK293FT cell model,
which is dependent upon high levels of expression, over-
whelms most of the cellular systems that might otherwise
modulate mutant SOD1 aggregation (proteasome degradation,
chaperone levels, etc.) providing insight in the inherent pro-
pensity of these proteins to self associate. Even in the face
of other modulating factors, the inherent propensity to aggre-
gate would be the basic force behind aggregation. At this basic
level, we ﬁnd that mutants that exhibit a high-aggregation pro-
pensity are often associated with disease of short duration.
One other factor to consider is that most of the human cases
for which we have signiﬁcant data are examples of disease of
relatively short duration. Because the longer duration cases are
not equally represented, the apparent association between
high-aggregation rates and short disease duration could be
due to bias in data set. However, statistical analyses of the
data indicate a non-random distribution of disease duration
among the classes of mutants, with high-aggregation propen-
sity more often being found in patients with short duration.
Moreover, within the group of patients that show short dur-
ation, 9 of 12 mutants that exhibited high-aggregation poten-
tial are associated with disease durations of less than 5
years. However, we clearly identify mutants that in cell
culture show aggregation propensities that do not ﬁt with
expectations for disease duration. Whether these exceptions
are truly examples of mutants that aggregate slowly and yet
are associated with rapidly progressing disease (e.g. D101N
mutant) or mutants that aggregate rapidly and yet are
associated with slowly progressing disease (e.g. E100K) is
uncertain. These may be examples in which the cell culture
system is not accurately predicting the in vivo situation or
these may be examples in which other modifying factors over-
shadow the role of aggregation in disease duration.
The association between aggregation of mutant SOD1 and
symptomatic disease duration, rather than onset, is a particu-
larly intriguing ﬁnding. In comparison to other neurodegenera-
tive diseases that have been associated with protein
misfolding, SOD1-associated ALS appears unique. For
example, in neurodegenerative disorders with expansions of
glutamine repeats regions, there is an association between
aggregation and age of disease onset rather than progression.
Individuals with polyglutamine expansions in the huntingtin
gene develop Huntington’s disease (HD). In HD, the length
of the polyglutamine tract strongly correlates with disease
onset, the larger the expansion the earlier onset (42,43); and
longer repeat lengths correlate with higher aggregation pro-
pensities of mutant huntingtin (44). In HD, disease duration
is not noted to be variable and the length of the polyglutamine
repeat does not correlate with disease duration (43). Another
example is Alzheimer’s disease (AD), which is deﬁned by
pathological accumulation of aggregated of b-amyloid pep-
tides in the brain. Familial forms of AD linked to mutations
in amyloid precursor protein or presenilin 1, lead to a net
increase in the amount of the highly aggregating b-amyloid
peptide 1–42 (45,46). These inherited forms of AD generally
show much earlier disease onsets, but disease durations are
similar to the sporadic disease (47,48). Thus, in other
examples of neurodegenerative disease associated with
protein misfolding and aggregation, the aggregation rates of
the causative protein appears to best correlate with disease
onset.
We provide evidence that mutations in SOD1 that are
associated with a high-aggregation propensity generally
predict a more rapidly progressing disease. However, several
exceptions are noted, and it becomes less predictable for
mutants with lower aggregation propensities. Thus, it
appears that at least two factors regulate disease progression;
one of which is high inherent aggregation propensity of
SOD1 mutant protein. In this view, we would categorize high-
aggregation propensity as a risk factor for rapidly progressing
disease. Studies from our laboratory, and others, have demon-
strated that, in mouse models of SOD1-associated ALS, the
most signiﬁcant accumulations of large mutant SOD1 aggre-
gates occurs late in disease (12,13,15,23,24,37–40). Impor-
tantly, signiﬁcant accumulation of mutant SOD1 aggregates
occurs well after the appearance of multiple pathological
abnormalities in these mouse models (40). Thus, we concur
with others that have suggested that there must be a toxic
form of mutant SOD1 that is distinct from larger protein
aggregates with these entities initiating disease. However,
aggregation of the mutant protein may be one of the forces
capable of modulating the rate of disease progression. The
mechanisms by which aggregation of mutant SOD1 promotes
disease progression are unclear at present. One hypothesis that
could apply is the idea that the accumulation of SOD1 aggre-
gates impairs the ability of the cell to maintain protein homeo-
stasis (49). The idea is that as chaperones become occupied in
unproductive attempts to dissolve protein aggregates, these
Human Molecular Genetics, 2009, Vol. 18, No. 17 3223activities are not available for productive functions in protein
folding. There is also evidence that cells accumulating protein
aggregates show reduced proteasome function (50). Together,
the disruption of these critical protein homeostatic processes
could cause a feed-forward cascade of impairment in protein
folding and metabolism that could underlie the rapid pro-
gression of disease that is seen in many of the mouse
models. If these mechanisms apply, then compounds that
modulate mutant SOD1 aggregation could be useful thera-
peutics in slowing the progression of this disease in humans.
MATERIALS AND METHODS
SOD1 cDNA constructs
The majority of the methods in this paper have been pre-
viously described (22,25). All mutant SOD1 proteins were
expressed in HEK293FT cells using the pEF-BOS expression
vector. A few of the SOD1 mutants cDNAs used have been
previously created into the pEF-BOS system (WT, A4V,
G37R, G41D, G85R, G93A and G93C SOD1) (23,51);
however, many other mutants were kindly provided, in the
YEp351 yeast vector, by Dr Stephen Holloway (University
of Texas Health Sciences Center, San Antonio, TX, USA),
which we subcloned into our pEF-BOS mammalian vector.
The sequences of all mutants in the pEF-BOS vector were ver-
iﬁed by automated sequence analysis.
Transfections and detergent extraction and
centrifugation assay
All mutants were transfected, using Lipofectamine 2000 (Invi-
trogen, Carlsbad, CA, USA), into HEK293FT cells for 24 or
48 h, as indicated in ﬁgure legends. Then cells were collected,
washed in 1  PBS and lysed by sonication in non-ionic deter-
gent (10 mM Tris, pH 7.5; 1 mM EDTA, pH 8.0; 100 mM NaCl;
0.5% NP-40, 1:100 v/v protease inhibitor cocktail from Sigma,
St Louise, MO, USA). Detergent soluble (S1) and insoluble
(P2) fractions were separated by our previously described
detergent extraction and centrifugation technique (22,25).
Detergent extractions for each mutant were repeated a
minimum of three times, up to 24 times for WT and A4V
SOD1 controls.
SDS–PAGE and immunoblotting
In each case, S1 (5 mg) and P2 (20 mg) fractions for each
mutant are boiled in Laemmli sample buffer that contains
5% b-mercaptoethanol (bME) and electrophoresed in 18%
SDS–PAGE gels. Transfer onto nitrocellulose membranes
lasted only 2 h and immunoblotting by human SOD1 at
1:2500 was done overnight. PBS-T (1  PBS, 0.1% Tween
20) was used for membrane washes between antibody incu-
bations. As secondary antibody we used a goat anti-rabbit anti-
body at 1:5000 dilution (KPL, Gaithersburg, MD, USA) for
1 h before developing with ECL reagents (Thermo Scientiﬁc
Inc., Rockford, IL, USA).
Statistical analysis
The aggregation propensity of SOD1 mutants is deﬁned as the
ratio of band intensity of detergent-insoluble versus soluble
fractions (P2/S1) (22,23,25). As means to compare SOD1
mutants in different gels, the mean aggregation propensities
were normalized by assigning a value of one for our A4V
SOD1 positive control (22,23,53). Differences between WT
and mutant SOD1 proteins were assessed by paired Student
t-tests. Correlations and t-tests were performed using Graph-
Pad Prism 5.0 software (San Diego, CA, USA).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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